2025 International Congress » Huntington's Disease

A mindfulness-based intervention course in pre-manifest Huntington’s disease: analysis of pilot data

S. Berman, R. Devenyi, V. Vaughn, G. Toti, A. Lasker (Camden, USA)

Analysis of Emergency Department Encounters and Hospital Admissions of People with Huntington’s Disease

T. Orem, E. Forbes, S. Sillau (Aurora, USA)

Arginase2 – a potential mediator in the pathology of the stratum

M. Nalepa, K. Synoradzki, A. Skweres, A. Owczarek, M. Gewartowska, M. Wegrzynowicz (Warsaw, Poland)

Ataxia, the initial symptom in a patient with Huntington’s Disease and Acquired (non-Wilsonian) Hepatocerebral Degeneration

V. Montero, N. Valdés, á. Pontoni, P. Salles (Santiago de Chile, Chile)

Autonomic Nervous System Dysfunction in Patients with Huntington’s Disease: Preliminary Results Using the COMPASS-31 Scale

J. Patino, S. Zadegan, N. Rocha, E. Furr Stimming (Houston, USA)

Blood-based somatic CAG repeat expansion and clinical progression in Huntington’s disease patients from Western China

SR. Zhang, YF. Cheng, CY. Li, HF. Shang (Chengdu, China)

Burden of Non-Motor Manifestations in Huntington’s disease patients – A cross-sectional study in a teaching hospital in India.

M. Prathyusha, D. Radhakrishnan (New Delhi, India)

Co-occurrence of Spinal Muscular Atrophy Type 2 and Huntington’s Disease

U. Agarwal, S. Fu, Y. Wang, B. Bulica (Detroit, USA)

Comparative Efficacy and Safety of VMAT2 Inhibitors for Chorea in Huntington’s Disease: A Systematic Review and Meta-Analysis

A. Abunamoos, M. Mustafa, F. Alnajjar, Y. Aljazi, K. Moghib, N. Hamam, M. Alghaniem (Amman, Jordan)

Correlations of plasma glial fibrillary acidic protein levels with glymphatic system impairment in Huntington’s disease

JH. Yin, LY. Lu, Q. Yang, Y. Huang (Beijing, China)

Decreased Disease Burden in Motor-Related HD-HI Domains Among Adults With Huntington’s Disease Treated With Valbenazine

E. Furr Stimming, H. Zhang, O. Klepitskaya, D. Haubenberger, S. Hinton, C. Heatwole (Houston, USA)

Efficacy and Safety of Deutetrabenazine in Huntington’s Disease: a Systematic Review

A. Viapiana, V. Müller, L. Lima, A. Petry, R. Juvêncio, A. Ribeiro, D. Gonçalves, M. da Rosa, G. Maia, V. Xavier (Porto Alegre, Brazil)

Exploring the Characteristic Features of Speech and Facial Expressions in Patients with Huntington’s Disease Based on Machine Learning

L. Lu, J. Yin, N. Yan, Y. Huang (Sydney, Australia)

Huntington disease in a Patient with Extensive Psychiatric History

A. Sim, A. Drozdov, D. Carrillo, L. Acosta (El Paso, USA)

Huntington’s Disease: Overview from 20 Years of a Single-Center Experience

M. Tsalta-Mladenov, M. Levkova, M. Hachmeriyan, L. Angelova (Varna, Bulgaria)

Long-term results of pallidal deep brain stimulation in patients with Huntington’s disease

A. Gamaleya, A. Poddubskaya, S. Asriyants, A. Tomskiy (Moscow, Russian Federation)

Long-Term Safety and Efficacy of Valbenazine for Treating Huntington’s Disease Chorea

E. Furr Stimming, E. Kayson, S. Karpuram, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, E. Dunayevich, D. Haubenberger (Houston, USA)

Malnutrition Risk in Huntington’s Disease: A Cohort Study on Prevalence and Prognosis with Mendelian Randomization Validation

YF. Cheng, HF. Shang (Chengdu, Sichuan, China)

Patient Experience and Satisfaction With Once-Daily Deutetrabenazine Extended-Release Tablets for Treatment of Huntington Disease-Related Chorea

B. Bulica, M. Konings, S. Thompson, A. Yang, S. Kotak, P. Gandhi (Detroit, USA)

Safety, Feasibility, and Effects of Time-Restricted Eating in Early-Stage Huntington’s Disease: Preliminary Analysis of a Clinical Pilot Trial

R. Wells, L. Neilson, A. Hiller (Portland, USA)

Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease

E. Furr Stimming, E. Kayson, R. Mehanna, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, D. Haubenberger (Houston, USA)

Widespread White Matter Changes in Manifest Huntington’s Disease

S. Zadegan, TM. Cordeiro, E. Furr Stimming, A. Teixeira, N. Rocha (San Antonio, USA)